These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 7482818)

  • 21. Prevention and treatment of cytomegalovirus disease in thoracic organ transplant patients: evidence for a beneficial effect of hyperimmune globulin.
    Valantine HA
    Transplant Proc; 1995 Oct; 27(5 Suppl 1):49-57. PubMed ID: 7482821
    [No Abstract]   [Full Text] [Related]  

  • 22. The natural course of cytomegalovirus infection and disease in renal transplant recipients.
    Hartmann A; Sagedal S; Hjelmesaeth J
    Transplantation; 2006 Jul; 82(2 Suppl):S15-7. PubMed ID: 16858268
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytomegalovirus disease in liver transplant recipients: impact of acyclovir prophylaxis.
    Kizilisik TA; Preiksaitis JK; Kneteman NM
    Transplant Proc; 1993 Jun; 25(3):2282-3. PubMed ID: 8390739
    [No Abstract]   [Full Text] [Related]  

  • 24. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation.
    Ricart MJ; Malaise J; Moreno A; Crespo M; Fernández-Cruz L;
    Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii25-ii32, ii62. PubMed ID: 15814546
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term renal graft function and survival in patients with high-risk for cytomegalovirus infection receiving preemptive therapy.
    Alberú J; Morales-Buenrostro LE; Correa-Rotter R; Muñoz-Trejo T; Zúñiga-Varga J; Cuéllar-González JV; Mayorga-Madrigal H; Vanegas-Carrero R; Aranda F; Rodríguez-Romo R; Herrera-Garcia C; González-Michaca L; Sierra-Madero JG
    Rev Invest Clin; 2008; 60(5):365-74. PubMed ID: 19227433
    [TBL] [Abstract][Full Text] [Related]  

  • 26. How valid are risk factors for chronic transplant failure in renal transplant patients found in the literature with regard to our patients: results of a multivariate analysis.
    Kapsner T; Schneeberger H; Land W
    Transplant Proc; 1995 Feb; 27(1):878-80. PubMed ID: 7879217
    [No Abstract]   [Full Text] [Related]  

  • 27. The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection.
    Reischig T; Jindra P; Svecová M; Kormunda S; Opatrný K; Treska V
    J Clin Virol; 2006 Jun; 36(2):146-51. PubMed ID: 16531113
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta-analysis.
    Bonaros N; Mayer B; Schachner T; Laufer G; Kocher A
    Clin Transplant; 2008; 22(1):89-97. PubMed ID: 18217909
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytomegalovirus disease prophylaxis in seronegative recipients of kidneys from seropositive donors by combination of cytomegalovirus-hyperimmune globulin and low-dose acyclovir.
    MacDonald AS; Belitsky P; Cohen A; Lee S
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1355-6. PubMed ID: 1846463
    [No Abstract]   [Full Text] [Related]  

  • 30. Studies evaluating high-dose acyclovir, intravenous immune globulin, and cytomegalovirus hyperimmunoglobulin for prophylaxis against cytomegalovirus in kidney transplant recipients.
    Dickinson BI; Gora-Harper ML; McCraney SA; Gosland M
    Ann Pharmacother; 1996 Dec; 30(12):1452-64. PubMed ID: 8968459
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytomegalovirus infection in kidney transplantation: prophylaxis and management.
    Bulinski P; Toledo-Pereyra LH; Dalal S; Hernandez G
    Transplant Proc; 1996 Dec; 28(6):3310-1. PubMed ID: 8962286
    [No Abstract]   [Full Text] [Related]  

  • 32. CMV hepatitis after liver transplantation: incidence, clinical course, and long-term follow-up.
    Seehofer D; Rayes N; Tullius SG; Schmidt CA; Neumann UP; Radke C; Settmacher U; Müller AR; Steinmüller T; Neuhaus P
    Liver Transpl; 2002 Dec; 8(12):1138-46. PubMed ID: 12474153
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group.
    Falagas ME; Snydman DR; Ruthazer R; Griffith J; Werner BG; Freeman R; Rohrer R
    Clin Transplant; 1997 Oct; 11(5 Pt 1):432-7. PubMed ID: 9361936
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of cytomegalovirus prophylaxis on rejection following orthotopic liver transplantation.
    Slifkin M; Ruthazer R; Freeman R; Bloom J; Fitzmaurice S; Fairchild R; Angelis M; Cooper J; Barefoot L; Rohrer R; Snydman DR
    Liver Transpl; 2005 Dec; 11(12):1597-602. PubMed ID: 16315314
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of cytomegalovirus prophylaxis in renal retransplantation.
    Singh TP; Gruber SA; Lempert N; Freed B; Conti DJ
    Transplant Proc; 1995 Feb; 27(1):964-5. PubMed ID: 7879247
    [No Abstract]   [Full Text] [Related]  

  • 36. Effect of donor-recipient cytomegalovirus serologic status on outcomes in simultaneous kidney-pancreas transplant recipients.
    Stratta RJ; Alloway RR; Lo A; Hodge EE;
    Transplant Proc; 2004 May; 36(4):1082-3. PubMed ID: 15194376
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Living donor kidney transplantation across positive crossmatch: the University of Illinois at Chicago experience.
    Thielke JJ; West-Thielke PM; Herren HL; Bareato U; Ommert T; Vidanovic V; Campbell-Lee SA; Tzvetanov IG; Sankary HN; Kaplan B; Benedetti E; Oberholzer J
    Transplantation; 2009 Jan; 87(2):268-73. PubMed ID: 19155983
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ganciclovir prophylaxis delays but does not prevent cytomegalovirus infection in renal transplant recipients.
    Israni A; Krok K; Cohen D; Blumberg E; Bloom RD
    Transplant Proc; 2004 Dec; 36(10):3019-24. PubMed ID: 15686685
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation.
    Burns LJ; Miller W; Kandaswamy C; DeFor TE; MacMillan ML; Van Burik JA; Weisdorf DJ
    Bone Marrow Transplant; 2002 Dec; 30(12):945-51. PubMed ID: 12476289
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytomegalovirus prevention in combined kidney-pancreas transplantation using acyclovir alone.
    Elkhammas EA; Henry ML; Tesi RJ; Mutabagani K; Bryan BA; Ferguson RM
    Transplant Proc; 1994 Apr; 26(2):436. PubMed ID: 8171490
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.